Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
21247
Subbiah V, Sahai V, Maglic D, Bruderek K, Toure BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schonherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB.
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations.Cancer Discov
2023
PubMed ID: 37270847
DOI: 10.1158/2159-8290.CD-23-0475
18230
Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J.
Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell lineSci Rep
2022
12(1):19731.
PubMed ID: 36396974
DOI: 10.1038/s41598-022-24211-8
4046
Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, Kohno T.
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient CancersCancer Cell
2019
35(2):177-190
PubMed ID: 30686770
DOI: 10.1016/j.ccell.2018.12.009
11270
Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M.
VISTA expressed in tumour cells regulates T cell function.Br. J. Cancer
2019
PubMed ID: 30382166
DOI: 10.1038/s41416-018-0313-5
11333
Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.Mol Oncol
2019
PubMed ID: 30537101
DOI: 10.1002/1878-0261.12422
10231
Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.Mol. Cancer Ther.
2017
16:637-648
PubMed ID: 28119489
DOI: 10.1158/1535-7163.MCT-16-0415
4393
Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Neoplasia
2013
15(8):975-88
PubMed ID: 23908597
DOI: 10.1593/neo.121106
8749
Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, Ito K, Suzuki T, Sasano H, Yaegashi N, Hayashi S.
Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction.Endocr. Relat. Cancer
2008
15:451-63
PubMed ID: 18508998
DOI: 10.1677/ERC-07-0227
8772
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.
Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.Kobe J Med Sci
2007
53:177-87
PubMed ID: 18204294
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
DOI: 10.1002/ijc.11348
Back
Top
CELL BANK Website